Results 81 to 90 of about 5,502 (184)

Eptifibatide

Reactions weekly
Bansal AB, Sattar Y, Patel P, Jamil RT.
europepmc   +2 more sources

FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond

Journal of Peptide Science, Volume 30, Issue 11, November 2024.
This review provides an overview of FDA‐approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, and central nervous system diseases, and also addresses conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia.
Othman Al Musaimi
wiley   +1 more source

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

Cardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Huang Jianhua, Zhao Renyi, Pathak Alokkumar, Stouffer George A   +3 more
doaj   +1 more source

Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban

Кардиоваскулярная терапия и профилактика, 2008
The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI).
T. A. Batyraliev, D. V. Preobrazhensky, D. V. Fetzer, B. A. Sidorenko, S. A. Pataraya   +4 more
doaj  

Systematic adjudication of myocardial infarction end-points in an international clinical trial

Current Controlled Trials in Cardiovascular Medicine, 2001
Background Clinical events committees (CEC) are used routinely to adjudicate suspected end-points in cardiovascular trials, but little information has been published about the various processes used.
Lee Kerry L, Corbalon Ramón, Widimsky Petr, Bhapkar Manju, DeJong Ingrid, Granger Christopher B, Tardiff Barbara E, Crenshaw Brian S, Berdan Lisa G, Kleiman Neal S, Akkerhuis Martijn, Harrington Robert A, Mahaffey Kenneth W, Deckers Jaap W, Simoons Maarten L, Topol Eric J, Califf Robert M   +16 more
doaj   +1 more source

Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial [PDF]

, 2016
Ayman Elbadawi, Gerald Gasioch, Islam Y. Elgendy, Mahmoud Ahmed, Le Dung Ha, Haitham Al Ashry, Hend I. Shahin, Mohamed Hamza, Ahmed Abuzaid, Marwan Saad   +9 more
openalex   +1 more source

New drugs: Eptifibatide [PDF]

, 2003
Rhumab-E25 Study Group, W Busse, J Corren, B Lanier, M Mcalary, A Fowler-Taylor, Della Cioppa, G, H Milgrom, W Berger, A Nayak, N Gupta, S Pollard, M Mcalary, R E F E R E N C E S * 1, V Ho, A Gupta, R Kaufmann, G Todd, F Vanaclocha, R Takaoka, T Luger, E Van Leent, M Graeber, S Hedgecock, M Thurston, A Kandra, U Wahn, J Bos, M Goodfield, R Caputo, K Papp, A Manjra, R E F E R E N C E S * 1, S Singhal, J Mehta, R Desikan, D Ayers, P Roberson, P Eddlemon, L Mileshkin, J Biagi, P Mitchell, C Underhill, A Grigg, R Bell   +45 more
openalex   +1 more source

Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review

Revista Portuguesa de Cardiologia, 2019
This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention.
Daniel Caldeira, Hélder Pereira
doaj   +1 more source

Eptifibatide in Coronary Intervention [PDF]

, 2015
Matthew W. Sherwood, James E. Tcheng
openalex   +1 more source

Eptifibatide and 7E3, but Not Tirofiban, Inhibit α _v β ₃ Integrin–Mediated Binding of Smooth Muscle Cells to Thrombospondin and Prothrombin [PDF]

, 2002
Robert M. Scarborough
openalex   +1 more source